Chemical Component Summary

NameMOMETASONE FUROATE
Identifiers[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroethanoyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
FormulaC27 H30 Cl2 O6
Molecular Weight521.429
TypeNON-POLYMER
Isomeric SMILESC[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)OC(=O)c5ccco5)C)O)Cl)C
InChIInChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1
InChIKeyWOFMFGQZHJDGCX-ZULDAHANSA-N

Chemical Details

Formal Charge0
Atom Count65
Chiral Atom Count8
Bond Count69
Aromatic Bond Count5

Drug Info: DrugBank

DrugBank IDDB14512 
NameMometasone furoate
Groups
  • approved
  • investigational
  • vet_approved
DescriptionMometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label][F4292,F4295]. It has a glucocorticoid receptor binding affinity 22 times stronger than [dexamethasone] and higher than many other corticosteroids as well[A176906]. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indications[FDA Label][F4292,F4295].
Synonyms
  • Mometasone furoate
  • Mometasone furoate anhydrous
  • Mometasone furoate monohydrate
Brand Names
  • Quinixil
  • Taro-mometasone Lotion
  • Dulera
  • Nasonex Allergy and Congestion
  • Hyaluronic Acid Sodium Salt 2% / Mometasone Furoate 0.1% / Niacinamide 4%
IndicationInhaled mometasone furoate is indicated for prophylaxis of asthma in patients ≥4 years.[L9560] Applied topically as an ointment, mometasone furoate is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 years.[L9590] Mometasone furoate nasal spray is available both over-the-counter (OTC) and by prescription. The OTC nasal spray formulation of mometasone furoate is indicated for the treatment of upper respiratory allergic symptoms (e.g. rhinorrhea, sneezing) in patients ≥2 years of age.[L42300] The prescription formulation is indicated for the treatment of chronic rhinosinusitis with nasal polyps in patients ≥18 year old and for the and prophylaxis of seasonal allergic rhinitis in patients ≥12 years old.[L9563] It is also approved in combination with [olopatadine] for the symptomatic treatment of seasonal allergic rhinitis in patients ≥12 years.[L39845]
Categories
  • Adrenal Cortex Hormones
  • Adrenals
  • Adrenergics, Inhalants
  • Anti-Allergic Agents
  • Anti-Inflammatory Agents
ATC-Code
  • D07AC13
  • R03BA07
  • D07XC03
  • R01AD09
  • R03AK09
CAS number83919-23-7

Drug Targets

NameTarget SequencePharmacological ActionActions
Glucocorticoid receptorMDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAV...unknown
Progesterone receptorMTELKAKGPRAPHVAGGPPSPEVGSPLLCRPAAGPFPGSQTSDTLPEVSA...unknown
Cytochrome P450 2C8MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...unknowninhibitor
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate,inducer
Cytochrome P450 3A5MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...unknowninducer
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL1161
PubChem 441336
ChEMBL CHEMBL1161
ChEBI CHEBI:47564
CCDC/CSD SEGXEI, SEGXEI01, SEGXAE
COD 2020298